Form 8-K - Current report:
SEC Accession No. 0001193125-25-048423
Filing Date
2025-03-06
Accepted
2025-03-06 16:15:22
Documents
14
Period of Report
2025-02-28
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d861533d8k.htm   iXBRL 8-K 29508
2 EX-16.1 d861533dex161.htm EX-16.1 1809
  Complete submission text file 0001193125-25-048423.txt   158416

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syre-20250228.xsd EX-101.SCH 2831
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syre-20250228_lab.xml EX-101.LAB 18756
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syre-20250228_pre.xml EX-101.PRE 11697
16 EXTRACTED XBRL INSTANCE DOCUMENT d861533d8k_htm.xml XML 3776
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 25715429
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)